Previous 10 | Next 10 |
GERMANTOWN, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), Dong-a University Hospital in Sout...
GERMANTOWN, Md., March 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a c...
GERMANTOWN, Md., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be presenting...
Orgenesis is a $151m market cap biotech focused on cell and gene therapy technologies. It has a technology, therapeutics, and point of care platform that enables its CGT partners to develop products in a safe and sterile environment near to health / research centres. Last year, Or...
Orgenesis (ORGS): Q3 cash and cash equivalents of $88.8M.Revenue of $1.7M (+41.7% Y/Y)Press Release For further details see: Orgenesis reports Q3 results
Reports rapid advancement of therapeutic pipeline Announces new semi-automated cell and gene therapy processing units Reports cash and cash equivalents of $ 88.8 million as of September 30, 2020 GERMANTOWN, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) --...
GERMANTOWN, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, announced today that due to the public health impact of ...
GERMANTOWN, Md., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced completion of the prev...
Orgenesis (ORGS) inks agreement to acquire Koligo Therapeutics, a leader in personalized cell therapies.Pursuant to the merger agreement, ORGS will acquire all of the outstanding stock of Koligo from its shareholders (the founders and staff of Koligo and a subsidiary of Bergen Special Opportu...
Acquisition to support accelerated commercialization of Koligo’s KYSLECEL ® , a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis Goal to rapidly advance KT-PC-301, an autologous cell therapy ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 2.7% to $127.255 on volume of 88,797,787 shares Ascent Solar Technologies Inc (ASTI) rose 9.6% to $0.1183 on volume of 88,651,038 shares Crown Electrokinetics Corp. (CRKN) fell 19.0% to $0.040499 on volu...